KRYS
Price
$150.41
Change
+$2.24 (+1.51%)
Updated
Jul 14 closing price
Capitalization
4.35B
27 days until earnings call
XNCR
Price
$8.85
Change
+$0.02 (+0.23%)
Updated
Jul 14 closing price
Capitalization
629.86M
15 days until earnings call
Interact to see
Advertisement

KRYS vs XNCR

Header iconKRYS vs XNCR Comparison
Open Charts KRYS vs XNCRBanner chart's image
Krystal Biotech
Price$150.41
Change+$2.24 (+1.51%)
Volume$270.55K
Capitalization4.35B
Xencor
Price$8.85
Change+$0.02 (+0.23%)
Volume$432.97K
Capitalization629.86M
KRYS vs XNCR Comparison Chart in %
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. XNCR commentary
Jul 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and XNCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2025
Stock price -- (KRYS: $150.41 vs. XNCR: $8.85)
Brand notoriety: KRYS and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 75% vs. XNCR: 51%
Market capitalization -- KRYS: $4.35B vs. XNCR: $629.86M
KRYS [@Biotechnology] is valued at $4.35B. XNCR’s [@Biotechnology] market capitalization is $629.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.86B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than XNCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 5 bullish, 3 bearish.
  • XNCR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than XNCR.

Price Growth

KRYS (@Biotechnology) experienced а +7.64% price change this week, while XNCR (@Biotechnology) price change was +11.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.48%. For the same industry, the average monthly price growth was +21.25%, and the average quarterly price growth was +31.32%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 10, 2025.

XNCR is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+10.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.35B) has a higher market cap than XNCR($630M). KRYS YTD gains are higher at: -3.990 vs. XNCR (-61.488). KRYS has higher annual earnings (EBITDA): 140M vs. XNCR (-161.68M). KRYS has more cash in the bank: 617M vs. XNCR (470M). KRYS has less debt than XNCR: KRYS (9.66M) vs XNCR (67.8M). KRYS has higher revenues than XNCR: KRYS (333M) vs XNCR (127M).
KRYSXNCRKRYS / XNCR
Capitalization4.35B630M690%
EBITDA140M-161.68M-87%
Gain YTD-3.990-61.4886%
P/E Ratio35.53N/A-
Revenue333M127M262%
Total Cash617M470M131%
Total Debt9.66M67.8M14%
FUNDAMENTALS RATINGS
KRYS vs XNCR: Fundamental Ratings
KRYS
XNCR
OUTLOOK RATING
1..100
254
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
38100
SMR RATING
1..100
5797
PRICE GROWTH RATING
1..100
6165
P/E GROWTH RATING
1..100
974
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (70) in the Pharmaceuticals Major industry is in the same range as XNCR (78) in the Biotechnology industry. This means that KRYS’s stock grew similarly to XNCR’s over the last 12 months.

KRYS's Profit vs Risk Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for XNCR (100) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than XNCR’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for XNCR (97) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than XNCR’s over the last 12 months.

KRYS's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as XNCR (65) in the Biotechnology industry. This means that KRYS’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for KRYS (97) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew significantly faster than KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSXNCR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
73%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 6 days ago
71%
Declines
ODDS (%)
Bearish Trend 15 days ago
75%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
69%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTCWX13.77N/A
N/A
Fidelity Advisor Asset Manager 20% C
SXPCX50.87N/A
N/A
DWS S&P 500 Index C
AIVOX10.67N/A
N/A
American Century International Opps A
TMITX11.27N/A
N/A
Transamerica Mid Cap Growth I3
ELMFX18.03N/A
N/A
Lord Abbett Emerging Markets Equity F

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+1.51%
XNCR - KRYS
56%
Loosely correlated
+0.23%
ACLX - KRYS
56%
Loosely correlated
+1.36%
IDYA - KRYS
56%
Loosely correlated
+0.44%
CRNX - KRYS
55%
Loosely correlated
+3.41%
CGON - KRYS
54%
Loosely correlated
-3.07%
More